Neuromyelitis optica spectrum disorders (herein called NMO) is an autoimmune disease of the CNS characterized by astrocyte injury, inflammation, and demyelination. In seropositive NMO, immunoglobulin G autoantibodies against aquaporin-4 (AQP4-IgG) cause primary astrocyte injury. A passive transfer model of NMO was developed in which spatially targeted access of AQP4-IgG into the CNS of seropositive rats was accomplished by pulsed focused ultrasound through intact skin. Following intravenous administration of microbubbles, pulsed ultrasound at 0.5 MPa peak acoustic pressure was applied using a 1 MHz transducer with 6-cm focal length. In brain, the transient opening of the blood-brain barrier (BBB) in an approximately prolate ellipsoidal volume of diameter $3.5 mm and length $44 mm allowed entry of IgG-size molecules for up to 3-6 hours. The ultrasound treatment did not cause erythrocyte extravasation or inflammation. Ultrasound treatment in AQP4-IgG seropositive rats produced localized NMO pathology in brain, with characteristic astrocyte injury, inflammation, and demyelination after 5 days. Pathology was not seen when complement was inhibited, when non-NMO human IgG was administered instead of AQP4-IgG, or in AQP4-IgG seropositive AQP4 knockout rats. NMO pathology was similarly created in cervical spinal cord in seropositive rats. These results establish a noninvasive, spatially targeted model of NMO in rats, and demonstrate that BBB permeabilization, without underlying injury or inflammation, is sufficient to create NMO pathology in AQP4-IgG seropositive rats.
INTRODUCTION
Neuromyelitis optica spectrum disorders (herein called NMO) is an autoimmune disease of the central nervous system (CNS) characterized by inflammation and demyelination in spinal cord, optic nerve, and brain. In seropositive NMO circulating immunoglobulin G autoantibodies against water channel aquaporin-4 (AQP4), called AQP4-IgG, bind to AQP4 on astrocytes and cause injury by complement and cellular cytotoxicity mechanisms (1) (2) (3) (4) . Secondary inflammation and injury to oligodendrocytes result in demyelination and neurological deficit. Various other mechanisms may contribute to NMO disease pathogenesis such as antibody-dependent cellular cytotoxicity, complement bystander injury, sensitized T cells, and others (5) (6) (7) (8) (9) (10) .
Animal models of NMO are needed to investigate NMO disease pathogenesis mechanisms and to test therapeutics (reviewed in Refs. [11] [12] [13] [14] [15] ). The hallmarks of NMO pathology include astrocyte injury with loss of astrocyte markers AQP4 and glial fibrillary acidic protein (GFAP), an inflammatory response with granulocyte infiltration and microglial activation, centrovascular deposition of activated complement, blood-brain barrier (BBB) disruption, and demyelination (1, 3, 4, (16) (17) (18) . Passive-transfer models of seropositive NMO, in which AQP4-IgG is administered directly into brain and cerebrospinal fluid, have recapitulated some features of NMO pathology (18) (19) (20) (21) (22) (23) (24) . However, NMO pathology is not seen when rodents are made seropositive for AQP4-IgG (25, 26) , which is consistent with human data that NMO patients can be AQP4-IgG seropositive for many years without neurological symptoms (27) . Mild and variable NMO pathology has been created in AQP4-IgG seropositive rats by invasive CNS injury (25) or by maneuvers causing generalized inflammation (23, (28) (29) (30) to allow entry of circulating AQP4-IgG into the CNS.
The goal of this study was to develop a noninvasive approach to produce spatially targeted NMO pathology in AQP4-IgG seropositive rats without immune modulation. Another goal was to test the hypothesis that BBB permeabilization is sufficient to create NMO pathology in seropositive rats. Building on prior work showing efficacy and safety of pulsed focused ultrasound with microbubble cavitation to transiently permeabilize the BBB (31) (32) (33) (34) (35) and the blood-spinal cord barrier (36, 37) , here we adapted the focused ultrasound approach to deliver circulating AQP4-IgG into rat CNS. The technical details were optimized to produce robust NMO pathology in brain and spinal cord of AQP4-IgG seropositive rats following a single exposure to pulsed focused ultrasound and microbubble injection.
MATERIALS AND METHODS

Chemicals and Antibodies
Purified recombinant AQP4-IgG (rAb-53) was provided by Dr Jeffrey Bennett (Univ. Colorado, Denver) and (non-NMO) pooled human IgG (hIgG), as control, was purchased from Pierce Biotechnology (Rockford, IL). Some studies were done using an Fc hexamer complement inhibitor (Comp inh ) as reported (5), which inhibits the classical complement pathway by >98% for 8-12 hours after intravenous administration. Optison albumin-coated perflutren protein-type A microbubbles (2-4.5 mm diameter, half-time 2.5-4.5 minutes) were purchased from GE Healthcare (Milwaukee, WI). All reagents were prepared in phosphate-buffered saline. Unless otherwise specified all chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
Rats
Sprague-Dawley rats were purchased from Charles River Lab (Wilmington, MA). Experiments were done using weight-matched rats ($250 g), age 7-9 weeks. AQP4 knockout (AQP4 À/À ) rats in a Sprague-Dawley background were generated using CRISPR-Cas9 technology as described in Ref. (38) . Rats were maintained in air-filtered cages and fed normal rat chow in the University of California, San Francisco (UCSF) Animal Care facility. Procedures were approved by the UCSF Institutional Animal Care Use Committee (IACUC) (approval number AN108551).
Instrumentation and Transducer Characterization
A spherically focused ultrasound transducer (model A392S-SU, Olympus, Webster, TX) with 39-mm diameter and 60-mm focal length operating at a frequency of 1.0 MHz was used to generate the acoustic field. The transducer was driven by an arbitrary function waveform generator (33220 A Agilent Technologies, Palo Alto, CA) through a 50-dB power amplifier (240 L ENI, Inc., Rochester, NY). The focal pressure magnitudes and acoustic field patterns were measured using a calibrated acoustic hydrophone (0.5-mm diameter, HNR-500, Onda Corporation, Sunnyvale, CA) mounted on a 3-axis automated translational stage in front of the transducer in a degassed deionized water tank. The beam measurements were performed following standard procedures using pulsed burst mode, with 100 cycle burst count and 1 kHz repetition rate. Hydrophone output voltage was measured with a digital oscilloscope. Beam profiles in scanning plane transverse to and along the axis of the transducer were measured using 0.5 mm transverse and 1 mm longitudinal step sizes. Net applied electrical power was measured using a power meter and a 40-dB dual directional coupler, and levels required to achieve 0.1-1.0 MPa peak negative pressure in water were measured. In a separate setup, to estimate acoustic attenuation by the rat skull and spinal column, ex vivo experiments were done using an excised portion of an adult rat skull or spinal column as described in Refs. (37, 39) . Briefly, the excised skull was enclosed in a cylindrical tissue holder with thin polyethylene membranes on both sides and suspended in the water tank at the focal point between the transducer and hydrophone (0.2-mm diameter, HNP-0200, Onda Corp., Sunnyvale, CA). The transmission loss was estimated using insertion loss techniques, measuring the pressure difference between free-field and presence of skull or spine.
Setup for Ultrasound Treatment of Rats
As diagrammed in Figure 1A , the ultrasound transducer was mounted on a stereotaxic instrument (Model 902 Dual, KOPF, Tujunga, CA) with precision 3D adjustment in position and orientation. To assist the alignment of the beam focal zone with the targeted rat brain region, a custom 3D-printed conical adapter (Zortrax M200 3D printer) was attached to the transducer during positioning. This adapter featured a narrow pointer tip that was registered with the transducer focal position, and could be removed prior to sonication to avoid affecting the nominal beam profile. A separate manipulator was used for positioning of the acoustic coupling reservoir, consisting of an open-top thin polyethylene bag containing deionized, degassed water at room temperature. Coupling of the bag to the rat skin was achieved using compression and ultrasound gel (Scan Ultrasound Gel, Parker Laboratories, Fairfield, NJ). Once the ultrasound transducer was positioned within the reservoir, any bubbles adhering to the surface of the transducer were carefully removed and confirmed by direct visualization prior to sonication.
BBB Permeabilization in Rats
Rats were anesthetized using ketamine (100 mg/kg) and xylazine (10 mg/mL). Hair on the targeted area (head or cervical spine dorsum) was removed using an electric razor followed by depilatory cream (Nair lotion). The femoral vein was cannulated using PE-10 tubing for delivery of microbubbles, antibodies and other compounds. For BBB studies, rats were immobilized on the stereotaxic frame and (without incision) the Lambda landmark was located as the cross-point of the inter-aural line and sagittal suture midline of the skull, and the Bregma was located as 9.0 mm anterior to Lambda on the midline (for $250 g rats, The Rat Brain in Stereotaxic Coordinates [40] ). The acoustic focal point was manually positioned 2.5 mm lateral to the midline, 4 mm posterior to the Bregma, and 3 mm beneath the skin. In some studies, the control right hemisphere was exposed to ultrasound first, and then the left hemisphere immediately following intravenous injection of 5-8 Â 10 8 /mL (0.4 mL/kg body weight) microbubbles. Just prior to injection and ultrasound treatment the microbubbles were activated by vigorous shaking per manufacturer's instructions.
For most experiments ultrasound parameters were: 10 ms pulse length, 1 Hz pulse repetition rate, and 2 minutes duration. Power settings corresponding to peak-negative acoustic pressures of 0.3, 0.4, and 0.5 MPa in water were tested in initial dose-finding experiments. As markers of BBB permeability, 2% Evans blue dye (4 mL/kg body weight) and normal human IgG (hIgG, 5 mg/kg body weight) were injected intravenously at specified times following ultrasound exposure. Two hours later the rats were deeply anesthetized with an overdose of ketamine/xylazine and killed by transcardiac perfusion with heparinized saline containing 4% paraformaldehyde. The brains were collected for immunostaining and histology.
In some experiments the cervical spine from C4 to C6 at the dorsal midline was targeted to permeabilize the bloodspinal cord barrier. Anesthetized rats were immobilized on the stereotaxic frame as described above, and a custom support was positioned beneath the rat chest to flatten the spinal column from C2 to T2 for optimal exposure of the targeted C5 region. Microbubble administration and ultrasound exposure was done as described for brain above, except that a total exposure time of 4 minutes was used.
NMO Studies
Following dose-finding experiments, NMO studies were done using power settings for 0.5 MPa peak-negative acoustic pressure in water, with 2-minute duration for brain and 4-minute duration for spinal cord. AQP4-IgG (5 mg/kg body weight) was administered via femoral vein catheter just after ultrasound exposure and rats were killed 5 days later. Brain or spinal cord was collected, sectioned, and imaged using fluorescence microscopy as described in Ref. (38) . Control studies were done using AQP4 knockout rats, or using wildtype rats in which non-NMO human IgG was administered in place of AQP4-IgG, or using AQP4-IgG seropositive rats pretreated with Comp inh to inhibit complement.
Immunofluorescence and H&E Staining
Frozen-sections (thickness 7 mm) were immunostained as described in Ref. (41) . Briefly, sections were incubated in blocking solution (1% BSA containing 0.3% Triton X-100 in PBS) for 1 hour at room temperature, then incubated overnight at 4 C with primary antibodies against albumin (1:100; MP Biomedicals, Santa Ana, CA), human IgG molecule 1 (Iba-1; 1:400, Wako, Richmond, VA), or CD45 (1:50, Abcam, Cambridge, MA) followed by the appropriate species-specific Alexa Fluor-conjugated secondary antibody for 1 hour (5 lg/mL each, Invitrogen) at room temperature. Sections were mounted with Prolong Gold antifade reagent with DAPI (Invitrogen, Life Technologies, Eugene, OR) for visualization of immunofluorescence on a Leica fluorescence microscope or Nikon confocal microscope. Hematoxylin and eosin (H&E) staining on 7 mm of brain or cervical spinal cord sections was done using standard procedures.
Statistical Analysis
Data are presented as mean 6 SEM. Statistical analysis was performed using Prism 5 GraphPad Software package (San Diego, CA). The normality of the data was established by Bartlett's test for equal variances and a one-way ANOVA with Newmann-Keuls post-hoc test to compare groups.
RESULTS
Instrument Set-Up and Characterization of the Acoustic Field
The goal was to produce robust, transient permeabilization of the BBB at a defined location by ultrasound-induced stable microbubble cavitation without significant erythrocyte extravasation or inflammation. Experiments were done in rat brain in which the head was immobilized in a stereotaxic frame to deliver the ultrasound at defined coordinates. As diagrammed in Figure 1 , the focal point of the ultrasound transducer was localized and aligned to the target region using a fabricated guide cone, which was replaced by a reservoir containing degassed water with ultrasound gel applied between the reservoir and skin of the rat head. An indwelling intravenous catheter allowed delivery of microbubbles just before application of ultrasound, and other materials at specified times following ultrasound exposure.
The spatial acoustic pressure distribution produced by the focused ultrasound was mapped using a hydrophone detector submersed in a degassed water tank along with the transducer. The pressure profile at the focal zone was an elongated ellipse with full width at half maximum of diameter $3.5 mm and length $44 mm. The spatial peak acoustic pressure profile in the transverse and longitudinal planes in water are shown in Figure 2 . A similar energy deposition profile predicted in brain matter with significant attenuation of $40% by the rat skull and spine is expected (37, 39) in a manner that recapitulated in vivo geometry. 
BBB Permeabilization in Rats Following Pulsed Focused Ultrasound
A range of parameters (acoustic pressure, pulse width, exposure time) was tested initially using Evan's blue dye extravasation as a visual indicator of BBB permeabilization (Fig. 3A) . Photographs of the brain surface and coronal sections through the brain (Fig. 3B) show that Evan's blue extravasation depends on peak acoustic pressure in a highly nonlinear manner and that its spatial profile was long and narrow as expected from the acoustic field profile in Figure 2 . Evan's blue extravasation was not seen without microbubble infusion. Immunofluorescence in Figure 3C shows that the ultrasound produced extravasation of intravenously administered human IgG (molecular size $150 kDa), and of endogenous serum albumin ($66 kDa), with lesser extravasation seen for fibrinogen ($340 kDa). H&E-stained sections showed minimal or no erythrocyte extravasation or inflammatory cell infiltration (Fig. 3D) .
The kinetics of BBB permeabilization was determined by killing rats at different times after ultrasound and microbubble exposure, in which Evan's blue and human IgG were administered 2 hours prior to death (Fig. 4A) . Figure  4B shows Evan's blue extravasation for up to 3 hours after ultrasound exposure, with much less extravasation seen at 6 hours. A similar temporal pattern was seen for extravasation of human IgG (Fig. 4C) . No significant inflammation or bleeding was seen at 24 hours after ultrasound exposure by immunofluorescence for inflammatory cells (CD45) and activated microglial (Iba-1) (Fig. 4D) , and H&E staining (Fig. 4E) . in control studies including: nontreated rats, AQP4-IgG seropositive rats pretreated with complement inhibitor, rats given (non-NMO) IgG in place of AQP4-IgG, and seropositive AQP4 À/À rats. Representative of studies on 2-3 rats per group.
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NMO Pathology in Brain of Seropositive Rats Following Focused Pulsed Ultrasound
To produce NMO pathology in brain, ultrasound with microbubbles was applied to rats made seropositive for AQP4-IgG by intravenous injection of a well-characterized recombinant monoclonal human AQP4-IgG (Fig. 5A) . Death of rats at 3 hours after ultrasound exposure showed deposition of the human recombinant AQP4-IgG in elongated elliptical pattern (Fig. 5B ) similar to that seen for Evan's blue dye. To study NMO pathology, immunofluorescence of rat brain was done at 5 days after ultrasound exposure, staining for markers of astrocytes (AQP4 and GFAP), myelin (MBP), inflammation (Iba-1 and CD45), and activated complement (C5b-9). Figure 5C shows positive immunofluorescence for each of these markers in the brain hemisphere in which microbubbles were infused just prior to ultrasound exposure, but not in the contralateral hemisphere that was exposed to ultrasound but without microbubbles. An interesting observation was a greater loss of astrocytes and myelin in gray matter than in white matter.
Control studies were done to confirm that the NMO pathology required microbubble administration, complement, AQP4-IgG, and AQP4. As shown in Figure 5D , NMO pathology was not seen: (a) in the absence of microbubbles; 
NMO Pathology in Rat Spinal Cord
Similar studies were done in which the pulsed ultrasound was focused onto cervical spinal cord at the level of C5 in which the spinous processes are relatively shorter and flatter compared with thoracic or lumbar vertebrae, and in which there is little effect of respiration (Fig. 6A) . Initial studies of ultrasound power requirement showed 0.76 MPa peak acoustic pressure in water caused marked hemorrhage at the targeted spot in vivo, where 0.5 MPa in water produced transient blood-spinal cord barrier opening, as seen by extravasation of Evan's blue (Fig. 6A) , human IgG, albumin, and fibrinogen, with little erythrocyte extravasation (Fig. 6B) . No extravasation of human IgG, albumin, or fibrinogen was seen in control rats not exposed to ultrasound.
Ultrasound exposure using 0.5 MPa peak acoustic pressure with microbubbles for 4 minutes in AQP4-IgG seropositive rats resulted in NMO pathology in spinal cord after 5 days. Immunostaining of cervical spinal cord showed loss of astrocyte markers, demyelination, inflammation, and deposition of activated complement (Fig. 6C) , seen as spotty loss of AQP4, GFAP, and MBP, and staining for Iba-1, CD45, and activated complement C5b-9.
DISCUSSION
The results here establish the utility of pulsed focused ultrasound with stable microbubble cavitation to create NMO pathology in the CNS of AQP4-IgG seropositive rats, and demonstrate that transient BBB permeabilization is sufficient to produce NMO pathology. Characteristic pathological features of NMO, including astrocyte injury, inflammation, deposition of activated complement, and demyelination, were seen following exposure of AQP4-IgG seropositive rats to focused ultrasound with microbubbles, without inflammation, hemorrhage, or ischemia. NMO pathology was not seen without microbubbles, with administration of a complement inhibitor, when (non-NMO) human IgG was administered in place of NMO-IgG, or in AQP4-IgG seropositive AQP4 À/À rats. Our data support the conclusion that passive transfer of AQP4-IgG into the CNS can produce NMO pathology without underlying inflammation, sensitized T cells, or direct injury.
The ultrasound model established here advances the modeling of NMO pathogenesis using experimental animals. Prior rodent models of NMO involved administration of AQP4-IgG or NMO patient sera into the CNS by direct injection into brain or cerebrospinal space (18) (19) (20) (21) (22) (23) . Such models, though initially useful to demonstrate the pathogenicity of AQP4-IgG and for testing of some therapeutics, are nonphysiological. Other experimental animal models of NMO utilized rats made seropositive by systemic administration of AQP4-IgG or NMO patient sera. Whereas AQP4-IgG seropositive rats do not develop spontaneous NMO disease, some manifestations of NMO are seen following brain injury (25) or creation of an inflammatory environment by experimental autoimmune encephalomyelitis (23, 28, 30, 42) , infusion of activated T cells (6, 7, 9, 43) , or infusion of cytokines (29) . Another limitation of prior models has been the challenges in producing robust NMO pathology in spinal cord and optic nerve, the tissues that are most relevant to human NMO. The histopathology in NMO includes loss of AQP4 immunoreactivity, vasculocentric deposition of IgG and activated complement, inflammatory cell infiltration, and demyelination, with ultimate neuronal loss. The pathological changes in brain and spinal cord found herein are characteristic of NMO pathology. The use of focused ultrasound with microbubbles allows spatially targeted creation of robust NMO pathology in AQP4-IgG seropositive rats without the need to cause injury or inflammation. Also, the creation of spatially defined pathology allows study of an internal negative control, such as the nonexposed brain, which is not possible with some prior models.
This study builds on a considerable body of prior work demonstrating the utility of focused ultrasound with stable microbubble cavitation to permeabilize capillary endothelial barriers. Noninvasive, reversible, transient, and regional opening of the BBB has been shown to facilitate targeted delivery of large therapeutic molecules into the CNS, including antibodies, growth factors, nanomedicine formulations, and therapeutic cells (44) (45) (46) (47) (48) . Several preclinical studies support the safety of focused ultrasound with stable microbubble cavitation, which show minimal erythrocyte extravasation and inflammation under optimized conditions (35, 37, 44, 45, (49) (50) (51) . Currently, phase I human clinical trials are in progress using focused ultrasound with microbubble cavitation to open the BBB for doxorubicin administration to brain tumors (NCT02343991), and for safety and effectiveness of the ultrasound device ExAblate Transcranial (220 kHz) System (NCT02986932) and the SONOCLOUD implantable medical device (NCT03119961) in early Alzheimer disease.
We note technical challenges and limitations of the methodology described herein. Precise targeting of the acoustic focal volume is needed, as is reproducibility of exposure conditions. Targeting was accomplished here using a removable 3D printed focus cone and stereotaxic methodology. Careful selection of parameters for ultrasound exposure, including acoustic pressure, pulse width and repetition rate, and total exposure time, is important to produce stable microbubble cavitation under the experimental conditions. Consistent intravenous delivery of the activated microbubble preparation immediately before ultrasound exposure is important as well. The inclusion of suitable standards and controls is important to ensure reproducibility, as well as evaluation of possible injury and inflammation in target tissues produced by ultrasound exposure. Further improvements to the methods establish here might include real-time monitoring of stable microbubble cavitation and permeabilization of the BBB (49, 52, 53) . The use of ultrasound transducers with tighter focusing might be desirable for some more precise applications such as targeting the optic nerve.
In summary, the results here demonstrate the application of focused pulsed ultrasound with stable microbubble cavitation to allow entry of NMO autoantibody into brain and spinal cord of AQP4-IgG seropositive rats to produce NMO pathology. The observation that transient permeabilization of the BBB alone, without inflammation, immunomodulation, or injury, is sufficient to produce NMO pathology in seropositive rats addresses a long-standing question in the field. Future applications of ultrasound with microbubble cavitation in the NMO field may include investigation of novel disease pathogenesis mechanisms and therapeutics, generation of nonrodent experimental animal models of NMO, and delivery of biologic and cell therapeutics such as neural stem cells.
